MedTrace Logo

Clinical Trial of Recombinant Pneumococcal Protein Vaccine

NCT05622942 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-12-04

No results posted yet for this study

Summary

Streptococcus pneumoniae infections often cause serious health problems, especially in infants and the elderly. Failure to cover all polysaccharide types of vaccines is a greater problem for adults than for children.

The purpose of this study was to preliminarily evaluate the safety and immunogenicity of a recombinant pneumococcal protein vaccine applied to adults aged 50 years and older to provide a basis for subsequent clinical trial design.

Conditions

  • Pneumonia
  • Respiratory Tract Diseases
  • Respiratory Tract Infections

Interventions

BIOLOGICAL

PBPV

Intramuscular injection, 1 dose of 0.5ml inoculated on day 0

BIOLOGICAL

PPV23

Intramuscular injection, 1 dose of 0.5ml inoculated on day 0

Sponsors & Collaborators

  • CanSino Biologics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-11
Primary Completion
2023-09-14
Completion
2024-01-30

Countries

  • China

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05622942 on ClinicalTrials.gov